Renovorx Stock Analysis
| RNXT Stock | USD 1.29 0.08 6.61% |
RenovoRx is undervalued with Real Value of 3.66 and Target Price of 11.0. The main objective of RenovoRx stock analysis is to determine its intrinsic value, which is an estimate of what RenovoRx is worth, separate from its market price. There are two main types of RenovoRx's stock analysis: fundamental analysis and technical analysis.
The RenovoRx stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. RenovoRx is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. RenovoRx Stock trading window is adjusted to America/New York timezone.
RenovoRx |
RenovoRx Stock Analysis Notes
The company recorded a loss per share of 0.58. RenovoRx had not issued any dividends in recent years. RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To find out more about RenovoRx contact Shaun Bagai at 650 284 4433 or learn more at https://renovorx.com.RenovoRx Investment Alerts
| RenovoRx may become a speculative penny stock | |
| RenovoRx appears to be risky and price may revert if volatility continues | |
| RenovoRx has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (10.23 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RenovoRx currently holds about 10.77 M in cash with (10.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19. | |
| RenovoRx has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRxs Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial |
RenovoRx Upcoming and Recent Events
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
RenovoRx Largest EPS Surprises
Earnings surprises can significantly impact RenovoRx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2023-03-02 | 2022-12-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2022-03-30 | 2021-12-31 | -0.16 | -0.12 | 0.04 | 25 |
RenovoRx Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 1.3 K | Royal Bank Of Canada | 2024-06-30 | 203 | Bank Of America Corp | 2024-06-30 | 182 | Family Firm Inc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Adar1 Capital Management Llc | 2024-09-30 | 315.2 K | Geode Capital Management, Llc | 2024-09-30 | 232.9 K | Watch Point Trust Co | 2024-09-30 | 97.2 K | Millennium Management Llc | 2024-06-30 | 86.3 K |
RenovoRx Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.96 M.RenovoRx Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.98) | (6.63) | |
| Return On Capital Employed | (39.16) | (37.20) | |
| Return On Assets | (6.98) | (6.63) | |
| Return On Equity | 3.41 | 3.58 |
Management Efficiency
RenovoRx has return on total asset (ROA) of (0.7008) % which means that it has lost $0.7008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5512) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.58 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.63). At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 4.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.29) | (0.28) | |
| Tangible Book Value Per Share | (0.29) | (0.28) | |
| Enterprise Value Over EBITDA | (1.97) | (2.06) | |
| Price Book Value Ratio | (7.86) | (7.46) | |
| Enterprise Value Multiple | (1.97) | (2.06) | |
| Price Fair Value | (7.86) | (7.46) | |
| Enterprise Value | 22.4 M | 44.5 M |
The management strategies employed by RenovoRx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 0.993 | Return On Assets (0.70) | Return On Equity (1.55) |
Technical Drivers
As of the 25th of November, RenovoRx holds the Semi Deviation of 3.64, coefficient of variation of 895.91, and Risk Adjusted Performance of 0.094. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of RenovoRx, as well as the relationship between them.RenovoRx Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. RenovoRx middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for RenovoRx. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
RenovoRx Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RenovoRx insiders, such as employees or executives, is commonly permitted as long as it does not rely on RenovoRx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RenovoRx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RenovoRx Outstanding Bonds
RenovoRx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. RenovoRx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RenovoRx bonds can be classified according to their maturity, which is the date when RenovoRx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
RenovoRx Predictive Daily Indicators
RenovoRx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of RenovoRx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
RenovoRx Forecast Models
RenovoRx's time-series forecasting models are one of many RenovoRx's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary RenovoRx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About RenovoRx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how RenovoRx prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling RenovoRx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as RenovoRx. By using and applying RenovoRx Stock analysis, traders can create a robust methodology for identifying RenovoRx entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current RenovoRx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. RenovoRx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. RenovoRx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 11.0 | Strong Buy | 3 | Odds |
Most RenovoRx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand RenovoRx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of RenovoRx, talking to its executives and customers, or listening to RenovoRx conference calls.
RenovoRx Stock Analysis Indicators
RenovoRx stock analysis indicators help investors evaluate how RenovoRx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading RenovoRx shares will generate the highest return on investment. By understating and applying RenovoRx stock analysis, traders can identify RenovoRx position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 4.4 M | |
| Common Stock Shares Outstanding | 10.3 M | |
| Total Stockholder Equity | -3 M | |
| Cash And Short Term Investments | 1.2 M | |
| Cash | 1.2 M | |
| Accounts Payable | 561 K | |
| Net Debt | -1.2 M | |
| 50 Day M A | 1.0438 | |
| Total Current Liabilities | 1.2 M | |
| Other Operating Expenses | 11.4 M | |
| Non Current Assets Total | 101 K | |
| Non Currrent Assets Other | 101 K | |
| Stock Based Compensation | 1.1 M |
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.